231 related articles for article (PubMed ID: 26525792)
1. Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.
Kuwata T; Enomoto I; Baba M; Matsushita S
Antimicrob Agents Chemother; 2016 Jan; 60(1):437-50. PubMed ID: 26525792
[TBL] [Abstract][Full Text] [Related]
2. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
3. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
4. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
Xiang SH; Farzan M; Si Z; Madani N; Wang L; Rosenberg E; Robinson J; Sodroski J
J Virol; 2005 May; 79(10):6068-77. PubMed ID: 15857992
[TBL] [Abstract][Full Text] [Related]
5. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
6. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
7. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
[TBL] [Abstract][Full Text] [Related]
8. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.
Qin Y; Banerjee S; Agrawal A; Shi H; Banasik M; Lin F; Rohl K; LaBranche C; Montefiori DC; Cho MW
PLoS One; 2015; 10(6):e0128823. PubMed ID: 26039641
[TBL] [Abstract][Full Text] [Related]
10. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.
de Taeye SW; de la Peña AT; Vecchione A; Scutigliani E; Sliepen K; Burger JA; van der Woude P; Schorcht A; Schermer EE; van Gils MJ; LaBranche CC; Montefiori DC; Wilson IA; Moore JP; Ward AB; Sanders RW
J Biol Chem; 2018 Feb; 293(5):1688-1701. PubMed ID: 29222332
[TBL] [Abstract][Full Text] [Related]
12. Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.
Agrawal-Gamse C; Lee FH; Haggarty B; Jordan AP; Yi Y; Lee B; Collman RG; Hoxie JA; Doms RW; Laakso MM
J Virol; 2009 Nov; 83(21):11005-15. PubMed ID: 19692476
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility.
Registre L; Moreau Y; Ataca ST; Pulukuri S; Henrich TJ; Lin N; Sagar M
J Virol; 2020 Jan; 94(2):. PubMed ID: 31694950
[TBL] [Abstract][Full Text] [Related]
14. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
Yusa K; Maeda Y; Fujioka A; Monde K; Harada S
J Biol Chem; 2005 Aug; 280(34):30083-90. PubMed ID: 15983047
[TBL] [Abstract][Full Text] [Related]
15. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
16. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
[TBL] [Abstract][Full Text] [Related]
17. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
Moody MA; Gao F; Gurley TC; Amos JD; Kumar A; Hora B; Marshall DJ; Whitesides JF; Xia SM; Parks R; Lloyd KE; Hwang KK; Lu X; Bonsignori M; Finzi A; Vandergrift NA; Alam SM; Ferrari G; Shen X; Tomaras GD; Kamanga G; Cohen MS; Sam NE; Kapiga S; Gray ES; Tumba NL; Morris L; Zolla-Pazner S; Gorny MK; Mascola JR; Hahn BH; Shaw GM; Sodroski JG; Liao HX; Montefiori DC; Hraber PT; Korber BT; Haynes BF
Cell Host Microbe; 2015 Sep; 18(3):354-62. PubMed ID: 26355218
[TBL] [Abstract][Full Text] [Related]
18. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.
Hatada M; Yoshimura K; Harada S; Kawanami Y; Shibata J; Matsushita S
J Gen Virol; 2010 May; 91(Pt 5):1335-45. PubMed ID: 20032207
[TBL] [Abstract][Full Text] [Related]
20. Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists.
Hikichi Y; Yokoyama M; Takemura T; Fujino M; Kumakura S; Maeda Y; Yamamoto N; Sato H; Matano T; Murakami T
J Gen Virol; 2016 Sep; 97(9):2427-2440. PubMed ID: 27368421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
